WebDoctor Encyclopedia

Keratinocyte carcinomas

Ocular surface squamous neoplasia (conjunctival squamous cell carcinoma)

Ocular surface squamous neoplasia covers precancerous change and squamous cell carcinoma of the conjunctiva and cornea. Sunlight, age, smoking and HIV raise the risk, and most cases are cured with chemotherapy eye drops or careful surgery.

Medically reviewed Last reviewed October 20, 2026

What is ocular surface squamous neoplasia?

Ocular surface squamous neoplasia, usually shortened to OSSN, is a group of growths that arise from the flat (squamous) cells covering the surface of the eye. These cells form the outer layer of the conjunctiva, the clear membrane over the white of the eye, and of the cornea, the clear window at the front of the eye.

OSSN covers a spectrum of disease. At the mild end, abnormal cells stay within the surface layer; this is called conjunctival or corneal intraepithelial neoplasia, a precancerous stage. At the other end is invasive squamous cell carcinoma, where cancer cells have broken through into the deeper tissue. Most people are diagnosed somewhere along this range.

OSSN is the most common non-pigmented tumour of the eye surface (Monroy et al., 2023). It mainly affects older people, especially men and those with a lot of sun exposure (Basti and Macsai, 2003). In parts of Africa, it is also common in younger adults living with HIV.

Most OSSN appears as a pink, jelly-like or white patch near the edge of the cornea. When it is found early, it can usually be cured with eye drops or minor surgery, and the eye and vision are preserved.

1. Key facts at a glance

Feature Details
What it is A spectrum from precancerous change to squamous cell carcinoma of the eye surface
Also called Conjunctival squamous cell carcinoma; conjunctival intraepithelial neoplasia (CIN) for the early stage
How common The most frequent non-pigmented tumour of the ocular surface
Typical age Usually over 60; younger with HIV
Main risk factors Sunlight, older age, male sex, smoking, HIV, HPV
Usual site Limbus, where the cornea meets the white of the eye
Main treatments Topical chemotherapy drops, or surgical excision with cryotherapy
Outlook Excellent for early disease; recurrence possible

2. Types of OSSN

Type Description Behaviour
Mild dysplasia (CIN I) Abnormal cells in the lower third of the surface layer Precancerous
Moderate dysplasia (CIN II) Abnormal cells in up to two-thirds of the layer Precancerous
Severe dysplasia or carcinoma in situ (CIN III) Abnormal cells through the full thickness, but not beyond Precancerous, high grade
Invasive squamous cell carcinoma Cancer cells invade below the surface layer Can spread locally and, rarely, further
Aggressive variants Mucoepidermoid and spindle cell carcinomas More likely to invade the eye or orbit

Appearance patterns

Pattern Description
Gelatinous Translucent, jelly-like, pink or grey
Papillary Raised with small finger-like projections and red dots of vessels
Leukoplakic White, chalky surface from keratin
Nodular A raised lump; more likely to be invasive
Diffuse Spreads flatly and can be mistaken for conjunctivitis

How OSSN compares with other eye surface growths

Growth Key features
Pinguecula Yellowish, flat or slightly raised; benign
Pterygium Wing-shaped tissue growing onto the cornea; benign
Conjunctival papilloma Benign, often HPV-related, usually in younger people
Conjunctival melanoma Usually pigmented; a different cancer
OSSN Gelatinous, papillary or white; often at the limbus; may have feeder vessels

3. Causes and risk factors

Risk factor Notes
Ultraviolet (UV) light The main environmental factor; more common near the equator
Older age Risk increases with age
Male sex Men are affected more often
Fair skin Higher risk with sun-sensitive skin
Smoking Increases the risk
HIV infection Raises the risk by about eight times (Carreira et al., 2013)
Human papillomavirus (HPV) A possible contributor; the evidence is strongest for certain HPV types
Immune suppression After organ transplantation, for example
Xeroderma pigmentosum A rare inherited condition with extreme UV sensitivity

A meta-analysis found a strong link with HIV. The evidence on HPV was more mixed, with the clearest association involving cutaneous (skin-type) HPV strains (Carreira et al., 2013).

Anyone diagnosed with OSSN at a young age, especially in regions where HIV is common, is usually offered an HIV test.

4. How does it look

On the eye

Feature Description
Colour Pink, red, grey or white
Texture Gelatinous, velvety or warty
Position Usually at the limbus, in the part of the eye exposed between the lids
Blood vessels Enlarged feeder vessels and small looped vessels within the lesion
Cornea A grey, frosted sheet spreading over the cornea in some cases

On imaging

High-resolution anterior segment optical coherence tomography (OCT) gives a cross-section of the eye surface. OSSN shows a thickened, bright surface layer with a sharp change from normal tissue. This test helps with diagnosis and with monitoring during treatment with eye drops (Monroy et al., 2023).

Under the microscope

Feature Description
Dysplasia Disordered, enlarged cells within the surface layer
Carcinoma in situ Full-thickness abnormal cells with an intact base
Invasive carcinoma Nests of cancer cells below the basement membrane
Keratin May form pearls in well-differentiated tumours

Impression cytology, where a small filter paper is pressed on the eye to collect surface cells, can also support the diagnosis without surgery (Basti and Macsai, 2003).

5. Symptoms

Common symptoms

  • A visible growth or patch on the white of the eye or at the edge of the cornea
  • Redness in one area that does not settle
  • Irritation, grittiness or a feeling of something in the eye
  • Watering

Less common symptoms

Symptom What it may mean
Blurred vision Growth over the cornea
Pain Deeper invasion or inflammation
Restricted eye movement or bulging Rarely, spread into the eye socket
Lump in front of the ear or in the neck Rarely, lymph node spread

When to seek medical advice

See an optician or eye doctor if you notice a new growth on the eye, or redness or irritation in one spot that lasts more than a few weeks. Persistent “conjunctivitis” on one side, especially in older people, should be checked.

6. Diagnosis

Test Purpose
Slit-lamp examination Magnified view of the eye surface
Photographs Record the lesion for comparison
Anterior segment OCT Non-invasive cross-sectional imaging
Impression cytology Collects surface cells without cutting
Biopsy or excision Confirms the diagnosis and depth
Ultrasound biomicroscopy Checks for invasion into the eye
CT or MRI of the orbit If spread into the eye socket is suspected
HIV test Recommended, especially in younger people

Staging

Invasive conjunctival carcinoma is staged with the TNM system:

Component What it describes
T (tumour) Size and invasion of nearby structures, such as the eyelid, the eye itself or the orbit
N (nodes) Spread to lymph nodes in front of the ear or under the jaw
M (metastasis) Distant spread, which is rare

7. Treatment

Topical chemotherapy (eye drops)

Over the past two decades, eye drops have become a main alternative to surgery. A meta-analysis found that topical treatment and surgical excision gave similar resolution and recurrence rates (Kozma et al., 2022).

Drug How it is used Notes
Interferon alfa-2b Drops several times a day for months Gentle; few side effects; slower to work
5-fluorouracil (5-FU) Drops in cycles, for example one week on and three weeks off Effective; mild to moderate irritation
Mitomycin C Drops in short cycles Very effective but more toxic; often second line

Interferon and 5-FU are often chosen first because they are well tolerated, while mitomycin C is kept for cases that do not respond (Monroy et al., 2023).

Surgery

Step Purpose
“No-touch” excision with wide margins Removes the tumour without spreading cells
Alcohol to the corneal part Lifts away abnormal surface cells
Cryotherapy (freezing) to the edges Destroys microscopic cells left at the margins
Grafting Amniotic membrane or conjunctiva covers the wound

Surgery is often preferred for nodular or suspected invasive tumours, sometimes combined with drops before or after.

Choosing between drops and surgery

Consideration Drops may suit Surgery may suit
Size and spread Large or diffuse lesions covering much of the surface Small, well-defined lesions
Suspected invasion Less suitable Preferred, so the tissue can be examined
Diagnosis Made by OCT or cytology Confirmed by the removed tissue
Effect on the eye surface Treats the whole surface, including hidden cells Can leave scarring or dryness
Commitment Weeks to months of regular drops A single procedure plus short recovery
Cost and access Some drugs are costly or hard to obtain Requires an eye surgeon and theatre time

Many specialists combine the two, for example using drops to shrink a large lesion before surgery, or after surgery to treat any remaining abnormal cells.

How eye drops are used safely

Chemotherapy eye drops are powerful medicines. Store them as instructed, often in the fridge. Keep them away from children and avoid touching the bottle tip to the eye. Wash your hands after use.

Your doctor may also suggest pressing gently on the inner corner of the eye for a minute after each drop, to limit drainage into the tear duct.

Advanced disease

Situation Treatment
Invasion into the eye Radiotherapy (plaque brachytherapy), or removal of the eye
Invasion into the orbit Orbital exenteration, sometimes with radiotherapy
Lymph node spread Neck or parotid surgery, radiotherapy
Unresectable or metastatic disease Immune checkpoint inhibitors are being explored

Side effects

Treatment Possible side effects
Interferon drops Mild redness, flu-like symptoms with injections
5-FU drops Redness, stinging, watering, lid irritation
Mitomycin C Pain, redness, damage to the surface cells and tear duct narrowing
Surgery and cryotherapy Dry eye, scarring, discomfort

In the meta-analysis, dry eye was the most frequent side effect overall and was reported in more than half of patients after surgery (Kozma et al., 2022).

What treatment involves day to day

Stage What to expect
Starting drops Instructions on dosing, handling and storage
During treatment Clinic checks every 4-8 weeks with photos or OCT
Surgery A day-case procedure under local or general anaesthetic
After surgery Antibiotic and steroid drops for a few weeks

8. Outlook (prognosis)

Situation Usual outlook
Intraepithelial neoplasia Excellent; usually cured with drops or excision
Small invasive carcinoma Very good with complete treatment
Recurrence Possible, especially with positive margins or large lesions
Invasion of the eye or orbit Less common; may require major surgery
Spread to lymph nodes or beyond Rare

Recurrences are more likely in people with HIV, large lesions, corneal involvement or incomplete removal.

9. Follow-up

Follow-up Purpose
Eye examinations every 3-6 months at first Checks for recurrence
Photographs and OCT Detect early regrowth
Yearly checks long term Recurrence can occur years later
Examination of the other eye OSSN can occur in both eyes
Lymph node checks For invasive tumours

10. Living with OSSN

  • Wear UV-blocking sunglasses and a brimmed hat outdoors
  • Use drops exactly as instructed, and wash your hands before and after
  • Use lubricating drops for dryness
  • Stop smoking
  • Attend HIV care regularly if you are living with HIV
  • Report new redness or growth promptly

11. Frequently asked questions

Question Answer
Is OSSN cancer? It ranges from precancerous change to squamous cell carcinoma
Will I lose my eye? Very rarely; most people keep their eye and vision
Can drops cure it without surgery? Often yes, especially for non-invasive disease
Is it caused by the sun? Sunlight is a major factor, along with age, smoking and infections
Why was I offered an HIV test? HIV greatly increases the risk, and treatment of HIV helps outcomes
Can it come back? Yes, so regular checks are needed
Does it spread? Spread beyond the eye is rare
Can I wear contact lenses? Usually not during treatment; ask your eye doctor

12. Questions to ask your care team

  • Is my OSSN intraepithelial or invasive?
  • Would eye drops or surgery suit me better?
  • Which drug do you recommend, and how long will treatment last?
  • What side effects should I watch for?
  • How often will I need check-ups?
  • Should I have an HIV test?

Resources

  1. Basti, S. and Macsai, M.S. (2003) ‘Ocular surface squamous neoplasia: a review’, Cornea, 22(7), pp. 687-704.
  2. Carreira, H. et al. (2013) ‘HIV and HPV infections and ocular surface squamous neoplasia: systematic review and meta-analysis’, British Journal of Cancer, 109(7), pp. 1981-1988.
  3. Kozma, K. et al. (2022) ‘Topical pharmacotherapy for ocular surface squamous neoplasia: systematic review and meta-analysis’, Scientific Reports, 12(1), 14221.
  4. Monroy, D. et al. (2023) ‘Medical treatment for ocular surface squamous neoplasia’, Eye, 37(5), pp. 885-893.

Prepared by the editorial team, October 2026.